Therapeutic Benefits of Lenalidomide in Hematological Malignancies
Lenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis. It is not only effective in myelodysplastic syndromes and myeloma, recent studies show...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-04-01
|
| Series: | Indian Journal of Medical Specialities |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/INJMS.INJMS_8_19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224502795304960 |
|---|---|
| author | Mohammed Shafi Abdulsalam Durai Mavalavan Vasudevan Manimoliyan |
| author_facet | Mohammed Shafi Abdulsalam Durai Mavalavan Vasudevan Manimoliyan |
| author_sort | Mohammed Shafi Abdulsalam |
| collection | DOAJ |
| description | Lenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis. It is not only effective in myelodysplastic syndromes and myeloma, recent studies show its effective action on newly diagnosed and relapsed/refractory lymphomas as well. Addition of lenalidomide to standard therapy is associated with lesser central nervous system relapse in diffuse large B-cell lymphomas. Lenalidomide shows promising results in Hodgkin's lymphomas and leukemias (acute myeloid leukemia and chronic lymphocytic leukemia). Dose escalation may be an option in nonresponders with caution in side effects. |
| format | Article |
| id | doaj-art-3c6c6c8c22bd4215af2edb9812e4d31f |
| institution | Kabale University |
| issn | 0976-2884 0976-2892 |
| language | English |
| publishDate | 2019-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Medical Specialities |
| spelling | doaj-art-3c6c6c8c22bd4215af2edb9812e4d31f2025-08-25T08:30:57ZengWolters Kluwer Medknow PublicationsIndian Journal of Medical Specialities0976-28840976-28922019-04-01102616510.4103/INJMS.INJMS_8_19Therapeutic Benefits of Lenalidomide in Hematological MalignanciesMohammed Shafi AbdulsalamDurai Mavalavan Vasudevan ManimoliyanLenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis. It is not only effective in myelodysplastic syndromes and myeloma, recent studies show its effective action on newly diagnosed and relapsed/refractory lymphomas as well. Addition of lenalidomide to standard therapy is associated with lesser central nervous system relapse in diffuse large B-cell lymphomas. Lenalidomide shows promising results in Hodgkin's lymphomas and leukemias (acute myeloid leukemia and chronic lymphocytic leukemia). Dose escalation may be an option in nonresponders with caution in side effects.https://journals.lww.com/10.4103/INJMS.INJMS_8_19lenalidomidelymphomamyelodysplastic syndromesmyeloma |
| spellingShingle | Mohammed Shafi Abdulsalam Durai Mavalavan Vasudevan Manimoliyan Therapeutic Benefits of Lenalidomide in Hematological Malignancies Indian Journal of Medical Specialities lenalidomide lymphoma myelodysplastic syndromes myeloma |
| title | Therapeutic Benefits of Lenalidomide in Hematological Malignancies |
| title_full | Therapeutic Benefits of Lenalidomide in Hematological Malignancies |
| title_fullStr | Therapeutic Benefits of Lenalidomide in Hematological Malignancies |
| title_full_unstemmed | Therapeutic Benefits of Lenalidomide in Hematological Malignancies |
| title_short | Therapeutic Benefits of Lenalidomide in Hematological Malignancies |
| title_sort | therapeutic benefits of lenalidomide in hematological malignancies |
| topic | lenalidomide lymphoma myelodysplastic syndromes myeloma |
| url | https://journals.lww.com/10.4103/INJMS.INJMS_8_19 |
| work_keys_str_mv | AT mohammedshafiabdulsalam therapeuticbenefitsoflenalidomideinhematologicalmalignancies AT duraimavalavanvasudevanmanimoliyan therapeuticbenefitsoflenalidomideinhematologicalmalignancies |